Should I buy or sell GlycoMimetics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLYC shares. View GLYC analyst ratings or view top-rated stocks .

What is GlycoMimetics' stock price target for 2024?

2 brokers have issued twelve-month target prices for GlycoMimetics' shares. Their GLYC share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 363.0% from the stock's current price. View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts .

How have GLYC shares performed in 2024?

GlycoMimetics' stock was trading at $2.36 at the start of the year. Since then, GLYC stock has decreased by 8.5% and is now trading at $2.16. View the best growth stocks for 2024 here .

Are investors shorting GlycoMimetics?

GlycoMimetics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,590,000 shares, an increase of 6.7% from the March 15th total of 1,490,000 shares. Based on an average trading volume of 367,100 shares, the days-to-cover ratio is presently 4.3 days. View GlycoMimetics' Short Interest .

When is GlycoMimetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our GLYC earnings forecast .

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings results on Friday, November, 3rd. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14). During the same quarter last year, the firm earned ($0.16) EPS.

What other stocks do shareholders of GlycoMimetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL) , TG Therapeutics (TGTX) , Viking Therapeutics (VKTX) , Cidara Therapeutics (cdtx) , Celldex Therapeutics (CLDX) , Dynavax Technologies (DVAX) , Spectrum Pharmaceuticals (SPPI) , Coherus BioSciences (CHRS) , Verastem (VSTM) and Aldeyra Therapeutics (ALDX) .

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free GLYC Stock Alerts

$2.16

-0.12 (-5.26%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.15
▼
$2.36
50-Day Range: $2.15
▼
$3.33
52-Week Range: $1.11
▼
$3.53

Volume: 875,980 shs
Average Volume: 408,448 shs
Market Capitalization: $139.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get GlycoMimetics alerts:

GlycoMimetics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 363.0% Upside
$10.00 Price Target
Short Interest: Bearish
2.47% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: 0.49
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.54) to ($0.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.02 out of 5 stars

Medical Sector

167th out of 918 stocks

Pharmaceutical Preparations Industry

59th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
GlycoMimetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
GlycoMimetics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.47% of the outstanding shares of GlycoMimetics have been sold short.
Short Interest Ratio / Days to Cover
GlycoMimetics has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in GlycoMimetics has recently increased by 6.71%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
GlycoMimetics does not currently pay a dividend.
Dividend Growth
GlycoMimetics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
GlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for GlycoMimetics is -0.55.

3.0

News and Social Media Coverage

News Sentiment
GlycoMimetics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for GlycoMimetics this week, compared to 1 article on an average week.
Search Interest
26 people have searched for GLYC on MarketBeat in the last 30 days. This is an increase of 136% compared to the previous 30 days.
MarketBeat Follows
7 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GlycoMimetics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.70% of the stock of GlycoMimetics is held by insiders.
Percentage Held by Institutions
75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for GlycoMimetics are expected to grow in the coming year, from ($0.54) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GlycoMimetics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GlycoMimetics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GlycoMimetics has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About GlycoMimetics Stock (NASDAQ:GLYC)

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GLYC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GLYC Stock News Headlines

April 18, 2024 | americanbankingnews.com

GlycoMimetics, Inc. (NASDAQ:GLYC) Sees Significant Increase in Short Interest

April 15, 2024 | money.usnews.com

GlycoMimetics Inc

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 1, 2024 | finance.yahoo.com

Loss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-Term

March 28, 2024 | finance.yahoo.com

GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript

March 28, 2024 | markets.businessinsider.com

Positive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth Initiatives

March 28, 2024 | finance.yahoo.com

Q4 2023 GlycoMimetics Inc Earnings Call

March 27, 2024 | markets.businessinsider.com

Buy Rating on GlycoMimetics Backed by Strong Financials and Promising Phase 3 Trial of Uproleselan

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 27, 2024 | markets.businessinsider.com

Buy Recommendation for GlycoMimetics Based on Promising Upro Drug Prospects and Strong Pipeline

March 27, 2024 | investorplace.com

GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023

March 27, 2024 | sfgate.com

GlycoMimetics: Q4 Earnings Snapshot

March 27, 2024 | finance.yahoo.com

GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections

March 27, 2024 | businesswire.com

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

March 21, 2024 | seekingalpha.com

GlycoMimetics Can Become A Game Changer In Blood Cancers

March 16, 2024 | finance.yahoo.com

GLYC Apr 2024 2.500 call

March 16, 2024 | finance.yahoo.com

GLYC Apr 2024 2.500 put

March 16, 2024 | markets.businessinsider.com

GlycoMimetics Inc hosts conference call for investors

March 16, 2024 | finance.yahoo.com

GLYC Apr 2024 5.000 call

March 14, 2024 | msn.com

Immuneering cancer drug shows initial clinical activity in early-stage trial

March 13, 2024 | barrons.com

Palatin Technologies Inc.

March 13, 2024 | businesswire.com

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

March 10, 2024 | morningstar.com

GlycoMimetics Inc GLYC

March 4, 2024 | finance.yahoo.com

Positive Signs As Multiple Insiders Buy GlycoMimetics Stock

February 26, 2024 | finance.yahoo.com

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

February 26, 2024 | businesswire.com

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

February 23, 2024 | finance.yahoo.com

GlycoMimetics, Inc. (GKO.F)

See More Headlines

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GLYC
CUSIP: N/A
CIK: 1253689
Web: www.glycomimetics.com
Phone: (240) 243-1201
Fax: 301-738-2137
Employees: 38
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $12.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +363.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,900,000.00
Net Margins: N/A
Pretax Margin: -368,990.00%
Return on Equity: -73.09%
Return on Assets: -64.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.41
Quick Ratio: 6.41

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 13,921.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.60 per share
Price / Book: 3.60

Miscellaneous

Outstanding Shares: 64,450,000
Free Float: 58,843,000
Market Cap: $139.21 million
Optionable: Optionable
Beta: 2.18

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Harout Semerjian (Age 54)
CEO, President & Director
Comp: $1.1M
Ms. Rachel K. King (Age 65)
Co-Founder & Director
Comp: $226.43k
Mr. Brian M. Hahn (Age 50)
Senior VP & CFO
Comp: $748.27k
Ms. Stephanie R. Irish CPA (Age 53)
Vice President of Accounting
Mr. Christian B. Dinneen-Long
General Counsel & Company Secretary
Mr. Bruce Johnson (Age 56)
Senior VP & Chief Commercial Officer
Dr. Edwin Rock M.D. (Age 63)
Ph.D., Senior VP & Chief Medical Officer
Mr. Chinmaya Rath (Age 47)
Senior VP & Chief Business Officer
Mr. Shantha Tyavanagimatt Ph.D.
Senior Vice President of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLYC Stock Analysis - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings or view top-rated stocks.
What is GlycoMimetics' stock price target for 2024?: 2 brokers have issued twelve-month target prices for GlycoMimetics' shares. Their GLYC share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 363.0% from the stock's current price.
View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts.
How have GLYC shares performed in 2024?: GlycoMimetics' stock was trading at $2.36 at the start of the year. Since then, GLYC stock has decreased by 8.5% and is now trading at $2.16.
View the best growth stocks for 2024 here.
Are investors shorting GlycoMimetics?: GlycoMimetics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,590,000 shares, an increase of 6.7% from the March 15th total of 1,490,000 shares. Based on an average trading volume of 367,100 shares, the days-to-cover ratio is presently 4.3 days.
View GlycoMimetics' Short Interest.

When is GlycoMimetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GLYC earnings forecast.
How were GlycoMimetics' earnings last quarter?: GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings results on Friday, November, 3rd. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14). During the same quarter last year, the firm earned ($0.16) EPS.
What other stocks do shareholders of GlycoMimetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX).
How do I buy shares of GlycoMimetics?: Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLYC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GlycoMimetics (GLYC) Stock Price, News & Analysis

GlycoMimetics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About GlycoMimetics Stock (NASDAQ:GLYC)

GLYC Stock Price History

GLYC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GLYC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™